Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)
Clinical trial NCT04965831 · UNKNOWN
Trial details
- NCT number
- NCT04965831
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-01
- Primary completion
- 2023-03-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.